NurExone Builds for Clinical Trials Armed with New Patent and $5.9M Cash Infusion

NurExone gains Australian exosome patent through 2040, raises $5.9M, and prepares ExoPTEN IND for spinal cord injury trial in 2026.

NurExone Biologic is entering a pivotal chapter with two key reinforcements in place: a freshly granted Australian patent that locks in exosome manufacturing rights through June 2040, and $5.9 million in capital raised during fiscal 2025 that lifted its cash balance to $2.14 million — triple the level a year earlier. Yet the company’s shares tell a more cautious story, trading at €0.35 after shedding more than 17% over the past twelve months and hovering near their 52-week low.

The patent, issued by IP Australia on April 23, covers the production of extracellular vesicles derived from stem cells and is exclusively licensed to NurExone. It complements existing intellectual property in Israel and the US, securing the manufacturing and commercialisation backbone for the company’s exosome platform. For a biotech on the cusp of human studies, reproducible and defensible production processes are essential before any therapy can scale, making this a structural rather than merely symbolic milestone.

All eyes are now on the US regulatory pathway. NurExone is preparing an Investigational New Drug application for ExoPTEN, its experimental therapy for acute spinal cord injuries. The goal is to initiate a Phase 1/2a trial within 2026 — a transition from preclinical work to first-in-human testing that would mark the company’s most significant operational leap to date. Management has cited FDA feedback and ongoing IND-enabling studies as the critical items on the checklist.

Delivering that message is the agenda for the Biomed Israel Conference and Exhibition in Tel Aviv from May 12 to 14. CEO Dr. Lior Shaltiel is expected to highlight ExoPTEN’s progress and the company’s readiness for the clinic. The conference appearance comes at a time when investors are looking for concrete regulatory timelines rather than aspirational statements.

Behind the scenes, the financial realities are stark. NurExone posted a net loss of $6.38 million last year, with research and development expenses consuming $2.64 million. Revenue remains zero, so the recently raised cash must stretch to cover IND preparation, manufacturing scale-up, and the early stages of clinical work. A clearer picture of the burn rate will emerge when first-quarter 2026 results are released.

On the operational front, the company has been expanding its North American footprint through a non-binding memorandum of understanding with BioXtek, targeting US-based GMP manufacturing and future commercial supply. Meanwhile, the scientific advisory board gained depth with the addition of Dr. Lars Bärfacker, a former Bayer researcher, for European expertise. Separately, researchers at Sheba Medical Center presented data on ExoPTEN in optic nerve regeneration models at a Denver conference earlier this month, adding preclinical visibility.

The stock’s 22% discount to its 200-day moving average and a 50% gap from the 52-week high reflect the market’s wait-and-see posture. For NurExone, the next weeks will be decisive: whether it can translate patent protection and a fortified balance sheet into a firm IND submission and a believable path to the clinic. Absent that precision, the recent patent win remains a solid piece of the puzzle — but not yet a breakthrough for shareholders.